tradingkey.logo

Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation From Its Ongoing Phase 1 Clinical Trial Of Pas-004 In Advanced Cancer

ReutersApr 10, 2025 11:12 AM

- Pasithea Therapeutics Corp KTTA.O:

  • PASITHEA THERAPEUTICS ANNOUNCES POSITIVE SAFETY REVIEW COMMITTEE (SRC) RECOMMENDATION FROM ITS ONGOING PHASE 1 CLINICAL TRIAL OF PAS-004 IN ADVANCED CANCER

  • PASITHEA THERAPEUTICS CORP - NO DOSE-LIMITING TOXICITIES (DLT'S) OR RASH OBSERVED TO DATE

  • PASITHEA THERAPEUTICS CORP - SRC RECOMMENDED THAT TRIAL ESCALATE TO NEXT DOSE LEVEL OF 30MG CAPSULE

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI